Hyqvia

Human Normal Immunoglobulin, the active ingredient in Hyqvia, is an immunoglobulin presented as a solution for subcutaneous injection use. It provides passive immunity by supplying IgG antibodies and is employed for immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.

GNH USA supplies Hyqvia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Hyqvia is used in the management of primary immunodeficiency disorders, providing essential IgG antibodies to reduce infection risk.

- Primary Immunodeficiency Diseases: restores IgG levels and decreases frequency of infections. - Common Variable Immunodeficiency (CVID): supplies missing antibodies to prevent recurrent infections. - X‑linked Agammaglobulinemia (XLA): provides IgG replacement to reduce bacterial and viral infections. - Severe Combined Immunodeficiency (SCID) post‑transplant: supports immune reconstitution after hematopoietic stem cell transplantation.

Hyqvia may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the administration site. - Headache: mild to moderate intensity. - Fatigue: transient tiredness following infusion. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: blood clots that may lead to serious complications. - Renal dysfunction: impaired kidney function, especially in patients with pre‑existing renal disease. - Aseptic meningitis: inflammation of the meninges without infection.

Before initiating Hyqvia therapy, several safety considerations should be observed.

- Baseline IgG assessment: determine immunoglobulin levels to guide dosing. - Renal function monitoring: check creatinine and eGFR regularly. - Hypersensitivity screening: evaluate for prior allergic reactions to immunoglobulins or hyaluronidase. - Thrombotic risk evaluation: avoid in patients with active clotting disorders. - Caution with anticoagulants: monitor for bleeding tendencies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hyqvia can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection due to immunosuppression. - Immunosuppressants (e.g., rituximab): can diminish the efficacy of immunoglobulin replacement. - Anticoagulants: increased risk of bleeding at injection sites due to hyaluronidase activity. - ACE inhibitors: potential for enhanced angioedema.

Moderate Interactions (Monitor Closely): - Antibiotics: overlapping toxicity, especially nephrotoxic agents. - Diuretics: may affect renal clearance of immunoglobulin. - Non‑live vaccines: efficacy may be reduced, monitor antibody response. - NSAIDs: may increase incidence of injection site reactions.